# Can GLP-1 Weight Loss Drugs Give Athletes an Unfair Advantage?
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) are raising questions about competitive fairness in sports. These medications suppress appetite and help people lose weight, but athletes who use them for weight management may gain performance advantages that concern sports organizations and medical experts.
The drugs work by slowing gastric emptying and signaling fullness to the brain. Athletes in weight-based sports, wrestling, boxing, and rowing have reportedly used GLP-1s to lose weight quickly before competitions. The concern centers on whether rapid weight loss creates unfair advantages over competitors who rely on traditional training and diet alone.
Sports governing bodies are taking notice. The World Anti-Doping Agency (WADA) currently classifies GLP-1s as non-prohibited substances for most athletes, but that status may change as evidence mounts. Some organizations worry these drugs could allow athletes to drop weight classes strategically or maintain muscle while shedding fat at rates difficult to achieve naturally.
Medical experts offer nuanced perspectives. Endocrinologists note that while GLP-1s are approved for weight management in the general population, using them purely for performance gains differs from therapeutic use. Dr. Robert Serfaty and other sports medicine physicians point out that the long-term effects on athletic performance remain unclear.
The ethical debate extends beyond competition. Parents and coaches face pressure to consider GLP-1 medications for young athletes trying to "make weight," even though these drugs carry side effects including nausea, vomiting, and gastrointestinal issues. The FDA has not approved GLP-1s for minors with obesity in most cases.
Some professional sports leagues are moving preem